B&L signs agreements with Pfizer and Santen

Article

Pfizer and Bausch & Lomb are to co-promote their prescription eye drugs in the United States, allowing both companies to increase significantly the support for the products, according to a joint statement released by the companies.

Pfizer and Bausch & Lomb are to co-promote their prescription eye drugs in the United States, allowing both companies to increase significantly the support for the products, according to a joint statement released by the companies.

The five-year agreement involves Pfizer's glaucoma drug, latanoprost (Xalatan), and three Bausch & Lomb products: loteprednol etabonate ophthalmic suspension 0.2% for conjunctivitis (Alrex); loteprednol etabonate ophthalmic suspension 0.5% for inflammatory conditions (Lotemax); and loteprednol etabonate 0.5% and tobramycin 0.3% ophthalmic suspension (Zylet), which is a combined anti-inflammatory and anti-infective agent.

Bausch & Lomb's besifloxacin, an anti-infective eye drop under review by the FDA, is also included in the deal. Pfizer will continue to maintain three mid-stage ophthalmic development programs in its own pipeline.

Under the new agreement, the sales forces from both companies will promote Xalatan, Alrex, Lotemax, Zylet and, pending FDA approval (expected by B&L sometime this year), besifloxacin.

"Working in collaboration, our US sales organizations will now represent one of the broadest product offerings in the US ophthalmic market," said Flemming Ornskov, global president of pharmaceuticals at Bausch & Lomb.

In a separate agreement, Bausch & Lomb has also entered into a licensing agreement with Santen Pharmaceuticals and has obtained the rights to Santen's hydrophobic acrylic polymers. B & L will use these polymers to commercialize new intraocular lenses (IOLs) for sale worldwide, with the exception of Japan.

Financial terms of the deals have not been disclosed.

Newsletter

Get the essential updates shaping the future of pharma manufacturing and compliance—subscribe today to Pharmaceutical Technology and never miss a breakthrough.

Recent Videos
Jeremiah Tao, MD, FACS, discusses his Egyptian Ophthalmological Society keynote, which focused on risk management and avoiding surgical complications in oculofacial surgery
Omer Trivizki, MD, MBA, a retina specialist from Tel Aviv Medical Center, speaks about VOY-101, a Novel, Complement-Modulating Gene Therapy for Geographic Atrophy at the American Society of Retina Specialists (ASRS) Annual Meeting
João Pedro Marques, MD, MSc, PhD discusses a retrospective study of 800 patients with inherited retinal diseases during the American Society of Retina Specialists (ASRS) annual meeting
© 2025 MJH Life Sciences

All rights reserved.